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ABSTRACT Whole-cell patch-clamp recordings and sin-
gle-cell Ca2+ measurements were used to study the control of
Ca2+ entry through the Ca2+ release-activated Ca2+ influx
pathway (ICRAC) in rat basophilic leukemia cells. When in-
tracellular inositol 1,4,5-trisphosphate (InsP3)-sensitive
stores were depleted by dialyzing cells with high concentra-
tions of Ins.P3, ICRAC inactivated only slightly in the absence of
ATP. Inclusion of ATP accelerated inactivation 2-fold. The
inactivation was increased further by the ATP analogue
adenosine 5'-[y-thio]triphosphate, which is readily used by
protein kinases, but not by 5'-adenylyl imidodiphosphate,
another ATP analogue that is not used by kinases. Neither
cyclic nucleotides nor inhibition of calmodulin or tyrosine
kinase prevented the inactivation. Staurosporine and bisin-
dolylmaleimide, protein kinase C inhibitors, reduced inacti-
vation ofICRAC, whereas phorbol ester accelerated inactivation
of the current. These results demonstrate that a protein
kinase-mediated phosphorylation, probably through protein
kinase C, inactivates ICRAC' Activation of the adenosine re-
ceptor (A3 type) in RBL cells did not evoke much Ca2+ influx
or systematic activation of ICRAC. After protein kinase C was
blocked, however, large ICRAC was observed in all cells and this
was accompanied by large Ca2+ influx. The ability of a
receptor to evoke Ca2+ entry is determined, at least in part,
by protein kinase C. Antigen stimulation, which triggers
secretion through a process that requires Ca2+ influx, acti-
vated ICRAC. The regulation of ICRAC by protein kinase will
therefore have important consequences on cell functioning.
In nonexcitable cells, hormones and neurotransmitters that
couple to the ubiquitous second messenger inositol 1,4,5-
trisphosphate (InsP3) produce a biphasic increase in cytosolic
free Ca2+ (1, 2). The early, transient phase predominantly
reflects Ca2+ release from internal stores, whereas the sec-
ondary, plateau phase reflects Ca2+ influx into the cell. This
Ca2+ influx is important not only for refilling the stores (3) but
also modulates the spatiotemporal pattern of Ca2+ wave
propagation through the cell (4, 5).
Various Ca2+ entry pathways have been observed in non-
excitable cells (1). It appears that the most widely distributed
Ca2+ entry mechanism is provided by the so-called capacita-
tive Ca2+ influx (6). In this latter mechanism, the filling state
of the internal stores regulates Ca2+ entry in that depletion of
the stores activates a Ca2+ entry pathway. This entry pathway,
which is voltage independent, inwardly rectifying, and selective
for Ca2+, has been termed ICRAC (Ca2+ release-activated Ca21
current; ref. 7). Depletion-activated Ca2+ currents have been
recorded in several nonexcitable cells (8, 9) including rat
basophilic leukemia cells (RBL-2H3; ref. 10). The mechanism
whereby ICRAC is activated, as well as its regulation, is largely
unknown. Biochemical experiments have led to the suggestion
that capacitative Ca2+ influx is under control of phosphory-
lation, but the site of action of the kinase is not clear (11-13).
In the present study, we have found that ICRAC is inactivated
by a protein kinase-mediated phosphorylation. Furthermore,
the ability of a receptor to evoke Ca2+ influx is determined by
protein kinase C. Because secretion has an absolute require-
ment for Ca2+ influx in RBL cells (14-16), this kinase-
mediated inactivation of ICRAC is likely to be of physiological
importance.
MATERIALS AND METHODS
Rat basophilic leukemia cells (RBL-2H3) were cultured as
described (10). Patch-clamp experiments were conducted in
the tight-seal whole-cell configuration (17) at room tempera-
ture (20-25°C) in standard saline solution containing 140 mM
NaCl, 2.8 mM KCl, 10 mM CaCl2, 2 mM MgCl2, 10 mM CsCl,
11 mM glucose and 10 mM Hepes-NaOH (pH 7.2). Sylgard-
coated, fire-polished patch pipettes had resistances of 2-3 MfQ
after filling with the standard intracellular solution, which
contained 145 mM potassium glutamate, 8 mM NaCl, 1 mM
MgCl2, 2 mM MgATP, 10 mM EGTA, 0.1 mM fura-2, 40 ,uM
InsP3 (Amersham), and 10mM Hepes-KOH (pH 7.2). In some
experiments, Ca2+ was clamped to 60 nM by varying the
EGTA/CaEGTA ratio. When the adenosine receptor was
stimulated, cesium glutamate replaced potassium glutamate in
the internal solution in order to block the outwardly rectifying
K+ current activated by receptor stimulation (18) and 100 ,uM
GTP was also included in the pipette solution, since the
receptor couples to phospholipase C through a heterotrimeric
G protein. High-resolution current recordings were acquired
by a computer-based patch-clamp amplifier system (EPC-9).
Capacitative currents were canceled before each voltage ramp
using the automatic capacitance compensation of the EPC-9.
Series resistance was between 5 and 12 Mfl and inactivation of
the Ca2+ current did not correlate with series resistance. RBL
cells possess an inward rectifying K+ current (19), whose I-V
relationship could overlap with ICRAC under the present
conditions. When cells were dialyzed without InsP3 (Ca2+
buffered to 60 nM to prevent passive activation of ICRAC), very
small currents were observed (<0.5 pA/pF at -80 mV; n = 10)
that were constant over a 10-min recording period. However,
to eliminate any contribution from the inward rectifying K+
current in our experiments, 10 mM Cs+ was always present in
the external solution. The Ca2+ current was analyzed at -80
mV. Currents were filtered at 2.3 kHz and digitized at 100 p,s.
Ramps were given every second (-100 to + 100 mV in 50 ms),
and cells were held at 0 mV between ramps. All currents were
leak subtracted by averaging the first three to six ramps after
breaking in and then subtracting this from all subsequent
Abbreviations: InsP3, inositol 1,4,5-trisphosphate; ATP[yS], adeno-
sine 5'-[,y-thio]triphosphate; NECA, 5'-(N-ethylcarboxamido)ad-
enosine; PMA, phorbol 12-myristate 13-acetate; ICRAC, Ca2+ release-
activated Ca2+ current; BAPTA, bis(2-aminophenoxy)ethane-
N,N,N',N'-tetraacetate.
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traces. Extracellular solution changes were made by local
pressure application from a wide-tipped micropipette placed
within 20 Amm of the cell. Intracellular [Ca2+] was monitored
with a photomultiplier-based system as described (20). The
fluorescent indicator dye fura-2 was loaded by diffusion from
the patch pipette. Intracellular [Ca2+] was calculated from the
fluorescence ratio (360/390) as described (20). For single-cell
Ca2+ measurements, coverslips were incubated in normal
saline solution (140 mM NaCl/2.8 mM KCl/1 mM MgCl2/2
mM CaCl2/11 mM glucose/10 mM Hepes-NaOH, pH 7.2) to
which 5 ,uM fura-2 acetoxymethyl ester (AM) had been added.
After 30 min, the coverslips were washed five times in normal
saline solution and then incubated at 37°C for 15 min. Single
cell Ca2+ levels were measured by using a photomultiplier-
based system as described above. Cells were sensitized to
antigen [2,4-dinitrophenyl-conjugated bovine serum albumin
(100 ng/ml)] by incubating the cells overnight with IgE (2
,tg/ml). Both IgE and antigen were kindly provided by I. Pecht
(Weizmann Institute of Science, Rehovot, Israel). Three dif-
ferent preparations of RBL cells were sensitized in this way,
since responses in mast cells are variable from batch to batch
(21).
Drugs were from Sigma with the exception of adenosine
5'-[,y-thio]triphosphate (ATP[,yS]) and 5'-adenylyl imido-






























Depletion of internal Ca2+ stores in rat basophilic leukemia
cells (RBL-2H3) by three independent procedures (inclusion
of InsP3 in the pipette, applying the Ca2+ ionophore ionomy-
cin, or dialyzing cells with high concentrations of Ca21 chela-
tors to passively deplete stores) activates the voltage-
independent, highly selective Ca2+ current termed ICRAC (10).
Fig. 1 shows that when single RBL-2H3 cells were dialyzed via
a patch pipette with solutions lacking ATP, ICRAC (activated by
inclusion of InsP3 in the pipette) decreased only 18% ± 4%
(mean ± SEM) after a 250-s whole-cell recording (Fig. 1 a and
d; n = 20 cells). However, when 2 mM ATP was included in
the pipette solution, ICRAC inactivated by 42% ± 4% (Fig. 1 a
and d; n = 15).
The present results differ from a previous report, which
failed to find any effect of ATP on either activation or
inactivation of ICRAC in RBL cells (10). The difference seems
to lie in the choice of Ca2+ chelator. We have used EGTA,
whereas the previous study used bis(2-aminophenoxy)ethane-
N,N,N',N'-tetraacetate (BAPTA). Using 10 mM BAPTA
instead of EGTA under paired experiments, we failed to see
an effect of ATP on inactivation of ICRAC, whereas ICRAC was
inactivated in cells from the same coverslip when EGTA was
used (n = 3). BAPTA has numerous pharmacological effects
in addition to chelating Ca2+ (22, 23), including blocking
protein kinase C (24). Since inactivation of ICRAC involves a
kinase, likely protein kinase C (see below), this pharmacolog-
ical action of BAPTA might account for the lack of inactiva-
tion to ATP previously reported (10). Clearly, caution is
required when interpreting results with BAPTA.
We considered that inactivation of ICRAC in the presence of
ATP might reflect a kinase-mediated phosphorylation. If this
is true then ATP[,yS], an ATP analogue that is readily used by
kinases but is relatively resistant to dephosphorylation by
phosphatases resulting in irreversible phosphorylation (25, 26)
should evoke greater inactivation ofICRAC. Dialyzing cells with
2 mM ATP[,yS] (instead of ATP) resulted in almost complete
inactivation of the Ca2+ current (Fig. 1 a and d; n = 11). This
inhibitory effect of ATP[yS] was not mimicked by 5'-adenylyl
imidodiphosphate, another nonhydrolyzable analogue ofATP
but one that is not utilized by kinases (27), where inactivation
was 23% ± 4% after a 250-s recording (n = 11). This indicates
FIG. 1. Protein kinase inactivates ICRAC. The Ca2+ current was
activated by depleting stores with 40 ,uM InsP3. EGTA (10 mM) was
included in the pipette solution to clamp the cytosolic Ca2+ to very low
values. The Ca2+ current was monitored by voltage ramps going from
-100 to + 100 mV in 50 ms, as described (7). (a) Raw data of ramps
measured at 50 s (when ICRAC had peaked) and 250 s in the presence
of the indicated adenine nucleotides. (b) Pooled data from all the cells
analyzed (20 cells for 0 mM ATP, 15 cells for 2 mM ATP, and 11 cells
for 2 mM ATP[,yS]). (c) Ramps (50 and 250 s, as in a) obtained in the
presence of pharmacological agents that interact with protein kinase
C. (d) Pooled data of these agents [6 cells for 100 nM phorbol
12-myristate 13-acetate (PMA), 7 cells for 2 ,uM staurosporine, and 5
cells for 500 nM bisindolylmaleimide]. Drugs were applied at 50 s,
when the Ca2+ current had peaked, and were maintained throughout.
that the inhibitory effects of ATP and ATP[,yS] are due to
kinase-mediated phosphorylation. Although it is difficult to
rule out refilling of stores, especially if the stores are very close
to the plasma membrane, the inactivation of ICRAC by ATP is
unlikely to reflect refilling of InsP3 stores for several reasons.
First, the high concentrations of InsP3 used (30-50 ,uM) would
maintain depleted stores. Maximal activation of ICRAC occurs
with 3 ,uM under our conditions, which differs from a previous
report that found 10-20 AM InsP3 was necessary to activate
ICRAC (10). Again, the difference lies in the chelator, in that the
previous report used BAPTA, a competitive inhibitor of the
InsP3 receptor (22). When Ca2+ was clamped to 60 nM, no
difference in the extent of inactivation was observed compared
with 10 mM EGTA (both had 2 mM ATP and 50 ,uM InsP3),
demonstrating little, if any, store refilling in the continuous
presence of high InsP3 levels. Second, the extent of inactiva-
tion ofICRAC byATP was increased further when ATP[-yS] was
used. ATP[yS] is not used by ATPases, so refilling of stores by
Ca2+-ATPases would not occur.
To identify the protein kinase(s), various activators and
inhibitors of known kinases were tested. When either cAMP or
cGMP (each at 100 ,M) was included in the pipette solution
(in addition to 2 mM ATP), no difference in the rate or extent
of inactivation of ICRAC was observed compared with exper-
iments in which the cyclic nucleotides were omitted (n = 6 in
both cases). Hence, neither cAMP- nor cGMP-dependent
protein kinases inactivate ICRAC under the present conditions.
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4) nor the tyrosine kinase inhibitor genistein (100 ,M; n = 4)
prevented inactivation of ICRAC, suggesting that neither cal-
modulin-dependent nor tyrosine kinases contribute signifi-
cantly to inactivation of ICRACG
However, the protein kinase C inhibitor staurosporine (2
,uM) reduced inactivation ofICRAC in the presence ofATP and
InsP3 (Fig. ld; n = 7). Staurosporine alone failed to activate
ICRAC (n = 3). The more selective kinase C inhibitor bisin-
dolylmaleimide (500 nM; ref. 28) also reduced inactivation of
ICRAC (Fig. ld). Since staurosporine and bisindolylmaleimide
both reduced inactivation of ICRAC, whereas conventional
inhibitors of other kinases did not, it seems likely that protein
kinase C inactivates ICRAC- Consistent with this notion was the
finding that direct activation of the kinase by the phorbol ester
PMA (100 nM; applied 50 s after obtaining whole-cell mode
when ICRAC had peaked) increased inactivation OfICRAC in the
presence of 2 mM ATP (Fig. ld; n = 6 cells). In two additional
cells, however, PMA did not clearly increase inactivation
compared with ATP alone.
Taken together, these results demonstrate that a protein
kinase inactivates ICRAC and, although one must always bear in
mind that the current specific inhibitors will inevitably affect
other kinases, the pharmacological profile of the kinase would
be compatible with protein kinase C. These results are in
agreement with previous studies that used Ca2+ measurements
in cell populations and that suggested that protein kinase C can
reduce capacitative Ca2+ influx (11-13). They extend those
studies by demonstrating a direct current suppression inde-
pendent of other factors such as receptor desensitization,
membrane potential, and pump activity. Using the Ca2+-
activated Cl- current to follow capacitative Ca2+ influx in
oocytes, two studies found a role for a kinase in regulating
Ca2I entry. Blocking protein phosphatases potentiated Ca2+
influx (9) and the phorbol ester PMA increased Ca2+ entry,
implicating kinase C (29). Sustained exposure to PMA sub-
sequently inhibited Ca2+ influx, demonstrating a dual role for
kinase C on Ca2+ influx in oocytes (30). In RBL cells, we did
not observe an initial potentiation of ICRAC with phorbol ester
but instead only the inhibition. On the other hand, capacitative
Ca2+ influx appears not to be inhibited by protein kinase C in
some cell types (31). Which one of the two effects is being




One interesting observation is that kinase-mediated inacti-
vation begins after a delay of #50 s (Fig. ld). If kinase activity
were constant, one might have expected a gradual increase in
ICRAC until it reached a steady-state value rather than a large
transient activation followed by some inactivation. This could
be explained if depletion of stores activated either a phos-
phatase or the inhibitory kinase. Because kinase C can be
activated by an increase in Ca2+ (32), and kinases can associate
tightly with channels in the plasma membrane (27), an increase
in subplasmalemmal Ca2+ arising from activation of ICRAC
might stimulate the kinase, resulting in inactivation of ICRACG
This would provide a means whereby activation and inactiva-
tion are tightly coupled and might also contribute to the
Ca2+-dependent inactivation of ICRAC (7).
We asked whether protein kinase inactivation of ICRAC had
a physiologital significance. RBL cells possess native A3
adenosine receptors, which increase InsP3 by coupling to
phospholipase C via a G protein (33). Surprisingly, however,
receptor stimulation evokes only transient Ca2+ influx despite
a robust increase in InsP3 levels (33). In whole-cell recordings,
5'-(N-ethylcarboxamido)adenosine (NECA), a nonmetaboliz-
able agonist of the A3 receptor, failed to activate ICRAC in a
significant fraction of the cells (50%; n = 8), and in those that
responded a Ca2+ current occurred that inactivated almost
completely. Responses of three different cells are shown in Fig.
2a and averaged data from eight cells are provided in Fig. 2b.
Consistent with this was that NECA evoked only a small Ca2+
plateau, indicative of weak Ca2+ entry, in fura-2 AM-loaded
single cells (Fig. 3b shows 'the averaged Ca2+ response of 20
single cells, and Fig. 3a depicts responses of three individual
cells). However, when staurosporine was coapplied with
NECA, then not only did all cells evoke prominent ICRAC but
the Ca2+ current was larger and inactivation was modest (Fig.
2 c and d). ICRAC evoked by NECA was identical to that
activated by ionomycin or InsP3 in terms of inward rectifica-
tion, voltage-independent gating, and positive reversal poten-
tial (>+30 mV). Consistent with the current measurements
was the finding that sustained Ca2+ influx was evoked when
staurosporine, at the same concentration at which it prevented
inactivation of ICRAC in whole-cell recordings, was coapplied
with NECA in single fura-2 AM-loaded cells (Fig. 3 c and d).
Now a prominent Ca2+ plateau was observed. This effect of
staurosporine was mimicked by bisindolylmaleimide at a con-
centration of 500 nM (Fig. 3c).
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FIG. 2. Receptor activation of the Ca2+ current is regulated by protein kinase C. (a) Responses of three different cells to the adenosine receptor
agonist NECA (20 AM). (b) Averaged data from eight cells. Note the rapid inactivation and that many cells evoke only a weak response. (c and
d) Coapplication of NECA and staurosporine (2 ,M) evokes a prominent Ca2+ current in all cells, which inactivates only slightly. c shows three
representative cells and d shows pooled data from all cells. (e andf) Antigen stimulation (2,4-dinitrophenyl-modified bovine serum albumin at 200
ng/ml) evokes a prominent Ca2+ current in all cells tested. The longer latency after antigen application reflects the numerous processes in its signal
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FIG. 3. Protein kinase C regulates receptor-operated Ca2+ influx. (b) Averaged response of 20 fura-2 AM-loaded single cells to 20 ,uM NECA.
(a) Three single cell responses. (c and d) Responses to coapplication of NECA and 2 ,tM staurosporine. d is the averaged response of 20 cells and
c shows responses of three individual cells. Also included in d is the averaged response of 20 cells that were exposed to NECA and GX-109230X
(500 nM), a more selective inhibitor of protein kinase C. A higher concentration of GX-109230X (2 j,M) evoked a larger response. (e and f)
Responses to antigen. f is the averaged response of 21 single cells, and e depicts responses of three individual cells.
The preceding results have demonstrated that activation of
protein kinase C by PMA inhibits ICRAC, while inhibition of
protein kinase C by staurosporine or bisindolylmaleimide can
substantially increase receptor-operated Ca2+ influx induced
by NECA. In principle, protein kinase-mediated inhibition of
ICRAC could at least partially account for the relatively small
size of the influx phase observed with NECA stimulation.
However, there are probably additional sites in the signal
transduction pathway where protein kinase C can interfere. It
is known that many receptors that couple to phospholipase C
desensitize, and protein kinase C has been implicated in this
fast desensitization process through phosphorylation of the
receptor, G protein, or phospholipase C (34). Inhibition in this
early chain of events would decrease the amount of InsP3
produced and therefore the extent of store depletion, resulting
in less capacitative Ca2+ influx. Protein kinase C might also
decrease the amount of Ca2+ released by InsP3; since it has
been reported to phosphorylate, and thereby regulate, the
InsP3 receptor (30). This could also reduce the amount of store
depletion and thus Ca2+ entry. NECA-evoked Ca2+ transients
do desensitize when the agonist is applied at an interval of 100
s (33), although it is not clear whether this reflects poor
refilling of the stores, inhibition of Ca2+ release, or receptor
desensitization. Our findings on InsP3-evoked ICRAC described
above reveal a direct site of kinase action on capacitative Ca2+
influx that is independent of receptor signaling. In these
experiments, we dialyzed cells with supramaximal concentra-
tions of InsP3 and interfered with kinase C activity after ICRAC
had peaked. Thus, receptor desensitization and InsP3 receptor
inhibition were bypassed. Under these conditions, protein
kinase C inhibits either ICRAC or the message coming from
depleted stores. It is not clear, and it is beyond the scope of this
study, to what extent each of the above-mentioned mechanisms
contributes to the negative feedback regulation of receptor-
mediated Ca2+ influx. Nevertheless, since ICRAC is the limiting
factor for Ca2+ influx, its inhibition is likely to be of paramount
importance. If this inhibition were a general feature of capac-
itative influx, then one would expect this mechanism to
operate even with receptor stimulation with nondesensitizing
agonists.
Mast cells and the related RBL cells secrete histamine and
serotonin after antigen stimulation. The secretion critically
requires Ca2+ influx through a non-voltage-gated Ca2+ entry
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RBL cells is unclear. Using perforated patch recordings, it has
been shown that antigen activates ICRAC in RBL cells, and it
was concluded that ICRAC is the predominant source of Ca2+
for secretion (35). In whole-cell dialysis experiments, we also
observed that antigen activates ICRAC (Fig. 2 e and f) as well
as a large Ca2+ plateau (Fig. 3 e andf). Since antigen activates
phosphotidylinositol breakdown, one might expect a concom-
itant activation of protein kinase C and hence inhibition of
ICRAC. The finding that antigen-evoked ICRAC was on average
-1.6 pA/pF compared with -2.8 and -4 pA/pF for NECA
and InsP3, respectively, would indeed point to such inhibition.
The large Ca2+ influx evoked by antigen (similar to that
evoked by NECA and staurosporine) despite the smaller ICRIAC
likely arises from the ability of antigen to activate the inward
rectifier K+ channel in RBL cells (36). This would clamp the
cells at negative potentials and thereby maintain a large driving
force for Ca2+ influx through ICRAC. This result stresses the
caution required when interpreting Ca2+ signals from un-
clamped cells. The fact that antigen could roitinely evoke
ICRAC without needing to block protein kinase C, unlike the
case with NECA, would suggest that the kinase block ofICRAC
is not strong in the case of antigen, since both stimulants
produce similar increases in InsP3 (11). The lack of strong
inhibition of ICRAC might be due to several possibilities. The
stimulation by antigen might result in a mild or slow stimula-
tion of the dual signaling pathway, producing levels of InsP3
sufficient to deplete stores but not enough kinase activation to
substantially inhibit ICRAC. This would be consistent with the
delay in the Ca2+ signal to antigen compared with NECA.
Alternatively, the stimulation might mainly be targeted at a
kinase C isozyme (of which five have been identified in RBL
cells) that does not effectively suppress ICRACG
Because antigen evokes secretion through a process depen-
dent on Ca2+ influx, Ca2+ entry through ICRAC should be an
important source of Ca2+ for secretion. ICRAC therefore does
more than merely refill depleted stores; it regulates key
physiological processes like secretion. Clearly, any factor that
regulates ICRAC, like protein kinase C, will have important
consequences on cell functions such as secretion.
CONCLUSIONS
Our results have directly shown that ICRAC is inhibited by a
protein kinase, probably kinase C. Since protein kinase C will
be activated by receptors that increase InsP3 levels, this
demonstrates an important negative feedback mechanism on
Ca2+ homeostasis and supports the dual signaling hypothesis
where InsP3 and protein kinase C interact to regulate the same
process (37). The inability of some receptors that couple to
InsP3 to evoke Ca2+ influx, like adenosine A3 receptors, may
be due in part to protein kinase C inhibition of ICRAC. Finally,
although the mechanism whereby depletion of stores activates
Ca2+ influx is unclear, our results indicate that any activating
signal may need to overcome the protein kinase inhibition.
This could be achieved if the activating mechanism involved
either stimulation of a phosphatase (to dephosphorylate the
kinase-mediated phosphorylations) or if a signal also inhibited
the kinase. The efficacy of the activating signal from depleted
stores may be governed by the prevalent kinase C activity.
We are grateful to Drs. Alison Brading, A. Artalejo, N. Suda, H.
Terlau, and W. Stuhmer for comments on the manuscript and to
Frauke Friedlein for excellent technical support.
1. Tsien, R. W. & Tsien, R. Y. (1990) Annu. Rev. Cell BioL 6,
715-760.
2. Berridge, M. J. (1993) Nature (London) 361, 315-325.
3. Parekh, A. B., Foguet, M., Lubbert, H. & Stuhmer, W. (1993) J.
Physiol. (London) 469, 653-671.
4. Girard, S. & Clapham, D. E. (1993) Science 260, 229-232.
5. Yao, Y. & Parker, I. (1993) J. Physiol. (London) 468, 275-296.
6. Putney, J. W. (1986) Cell Calcium 7, 1-12.
7. Hoth, M. & Penner, R. (1992) Nature (London) 355, 353-356.
8. Zweifach, A. & Lewis, R. S. (1993) Proc. Natl. Acad. Sci. USA 90,
6295-6299.
9. Parekh, A. B., Terlau, H. & Stuhmer, W. (1993) Nature (London)
364, 814-818.
10. Fasolato, C., Hoth, M. & Penner, R. (1993) J. Biol. Chem. 268,
20737-20740.
11. Montero, M., Garcia-Sancho, J. & Alvarez, J. (1993) J. Biol.
Chem. 268, 13055-13061.
12. Montero, M., Garcia-Sancho, J. & Alvarez, J. (1994) J. Biol.
Chem. 269, 3963-3967.
13. Tornquist, K. (1993) Biochem. J. 290, 443-447.
14. Beaven, M. A. & Cunha-Melo, J. R. (1988) Prog. Allergy 42,
123-184.
15. Ali, H., Cuhna-Melo, J. R., Saul, W. F. & Beaven, M. A. (1990)
J. Biol. Chem. 265, 745-753.
16. Mohr, F. C. & Fewtrell, C. (1987) J. Cell Biol. 104, 783-792.
17. Hamill, O., Marty, A., Neher, E., Sakmann, B. & Sigworth, F.
(1981) Pflugers Arch. 391, 85-100.
18. Qian, Y. X. & McCloskey, M. A. (1993) Proc. Natl. Acad. Sci.
USA 90, 7844-7848.
19. McCloskey, M. A. & Cahalan, M. D. (1990) J. Gen. Phys. 95,
205-227.
20. Neher, E. (1989) in Neuromuscular Junction, eds. Sellin, L. C.,
Libelius, R. & Thesleff, S. (Elsevier, Amsterdam), pp. 65-76.
21. Neher, E. (1991) Int. Arch. Allergy Appl. Immunol. 94, 47-50.
22. Richardson, A. & Taylor, C. W. (1993) J. Biol. Chem. 268,
11528-11533.
23. Penner, R. & Neher, E. (1988) FEBS Lett. 226, 307-313.
24. Dieter, P., Fitzke, E. & Duyster, J. (1993) Biol. Chem. Hoppe
Seyler 374, 171-174.
25. Eckstein, F. (1985) Annu. Rev. Biochem. 54, 367-402.
26. Chad, J. E. & Eckert, R. (1986) J. Physiol. (London) 378, 31-51.
27. Chung, S. K., Reinhart, P. H., Martin, B. L., Brautigan, D. &
Levitan, I. B. (1991) Science 253, 560-562.
28. Toullec, D., Pianetti, P., Coste, H., Bellevergue, P., Grand-Perret,
T., Ajakane, M., Baudet, V., Boissin, P., Boursier, E., Loriolle, F.,
Duhamel, L., Charon, D. & Kirilovsky, J. (1991) J. Biol. Chem.
266, 15771-15781.
29. Petersen, C. C. H. & Berridge, M. J. (1994) J. Biol. Chem. 269,
32246-32253.
30. Ferris, C. D., Huganir, R. L., Bredt, D. S., Cameron, A. M. &
Snyder, S. H. (1991) Proc. Natl. Acad. Sci. USA 88, 2232-2235.
31. Bird, G., Rossier, M. F., Obie, J. F. & Putney, J. W. (1993)1. Biol.
Chem. 268, 8425-8428.
32. Asaoka, Y., Nakamura, S., Yoshida, K. & Nishizuka, Y. (1992)
Trends Biochem. Sci. 127, 414-417.
33. Beaven, M. A., Rogers, J., Moore, J. P., Hesketh, T. R., Smith,
G. A. & Metcalfe, J. C. (1984) J. Biol. Chem. 259, 7129-7136.
34. Wojcikiewicz, R. J., Tobin, A. B. & Nahorski, S. R. (1993) Trends
Pharmacol. Sci. 14, 279-285.
35. Zhang, L. & McCloskey, M. A. (1995) J. Physiol. (London) 483,
59-66.
36. Gericke, M., Dar, O., Droogmans, G., Pecht, I. & Nilius, B.
(1995) Cell Calcium 17, 71-83.
37. Berridge, M. J. (1987) Annu. Rev. Biochem. 56, 159-193.
Physiology: Parekh and Penner
